Short Interest in Certara, Inc. (NASDAQ:CERT) Declines By 15.7%

Certara, Inc. (NASDAQ:CERT) was the recipient of a large decrease in short interest during the month of June. As of June 15th, there was short interest totalling 4,400,000 shares, a decrease of 15.7% from the May 31st total of 5,220,000 shares. Based on an average daily volume of 576,300 shares, the days-to-cover ratio is currently 7.6 days. Approximately 4.0% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. KeyCorp raised shares of Certara from a “sector weight” rating to an “overweight” rating and set a $23.00 price target on the stock in a report on Wednesday, April 10th. JMP Securities initiated coverage on Certara in a research report on Thursday, April 4th. They set a “market perform” rating on the stock. Finally, Barclays lowered their price target on Certara from $18.00 to $16.00 and set an “equal weight” rating for the company in a report on Friday. Seven research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $19.81.

Insider Buying and Selling

In other Certara news, insider Patrick F. Smith sold 14,427 shares of Certara stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $16.85, for a total value of $243,094.95. Following the transaction, the insider now owns 50,091 shares in the company, valued at $844,033.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.39% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Pineridge Advisors LLC purchased a new stake in Certara in the fourth quarter valued at $28,000. Global Retirement Partners LLC lifted its holdings in shares of Certara by 5,306.3% in the 1st quarter. Global Retirement Partners LLC now owns 1,730 shares of the company’s stock valued at $31,000 after buying an additional 1,698 shares during the period. YHB Investment Advisors Inc. purchased a new stake in shares of Certara in the first quarter worth about $47,000. Natixis Advisors L.P. grew its holdings in Certara by 13.4% during the third quarter. Natixis Advisors L.P. now owns 15,136 shares of the company’s stock worth $220,000 after acquiring an additional 1,791 shares during the period. Finally, Pacer Advisors Inc. raised its position in Certara by 1,704.0% during the fourth quarter. Pacer Advisors Inc. now owns 12,754 shares of the company’s stock valued at $224,000 after acquiring an additional 12,047 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Stock Performance

Certara stock traded down $0.21 during trading hours on Monday, hitting $13.64. 665,945 shares of the stock traded hands, compared to its average volume of 567,172. The firm’s 50 day moving average price is $15.98 and its 200-day moving average price is $16.86. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.26 and a quick ratio of 3.26. The stock has a market capitalization of $2.19 billion, a price-to-earnings ratio of -34.97, a P/E/G ratio of 4.65 and a beta of 1.53. Certara has a 1 year low of $11.81 and a 1 year high of $19.87.

Certara (NASDAQ:CERT) last issued its earnings results on Tuesday, May 7th. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). Certara had a negative net margin of 17.02% and a positive return on equity of 4.08%. The firm had revenue of $96.65 million during the quarter, compared to analysts’ expectations of $94.48 million. As a group, equities analysts expect that Certara will post 0.29 EPS for the current fiscal year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.